Haemonetics (NYSE: HAE) announced that it received FDA approval for its NexSys PCS plasma collection system with Persona PLUS ...
BOSTON, Feb. 23, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today ...
Haemonetics HAE has been banking on its growth drivers like the Plasma and Hospital business. New product launches also lead to market expansion. The stock carries a Zacks Rank #2 (Buy) currently.
BOSTON - Haemonetics Corporation (NYSE:HAE) announced today it received U.S. Food and Drug Administration 510(k) clearance for its NexSys PCS Plasma Collection System with Persona PLUS technology, ...
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements in this press release may include, without ...
Haemonetics Corporation’s HAE impressive Hospital business recovery is poised to drive growth in the upcoming quarters. The robust uptake of the NexSys PCS system bodes well for its long-term growth.
Javascript is required for you to be able to read premium content. Please enable it in your browser settings.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results